DDrare: Database of Drug Development for Rare Diseases

Searched query = "Leber hereditary optic neuropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Béfizal; Cyclosporine; GS010; Genetic: GS010; Idebenone; Lenadogene nolparvovec; NADH; PENDING; Pending; RAAV2-ND4; RAAV2/2-ND4 VECTOR; Recombinant AAV vector serotype 2 containing the human wild type mitochondrial ND4 gene; Recombinant Adeno-Associated Viral vector, serotype 2 (rAAV2/2) containing the human wild-type mitochondrial NADH Dehydrogenase 4 gene (ND4); VA

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03153293 (ClinicalTrials.gov)	December 27, 2017	10/5/2017	A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy	A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy	Leber Hereditary Optic Neuropathy	Drug: rAAV2-ND4	Huazhong University of Science and Technology	Shiyan Taihe Hospital	Active, not recruiting	10 Years	65 Years	All	159	Phase 2;Phase 3	China
2	NCT01267422 (ClinicalTrials.gov)	April 2011	27/12/2010	Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)	Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy	Leber Hereditary Optic Neuropathy	Drug: rAAV2-ND4	Bin Li	Huazhong University of Science and Technology	Completed	8 Years	60 Years	All	9	N/A	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03153293
(ClinicalTrials.gov)

December 27, 2017

10/5/2017

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Leber Hereditary Optic Neuropathy

Drug: rAAV2-ND4

Huazhong University of Science and Technology

Shiyan Taihe Hospital

Active, not recruiting

10 Years

65 Years

All

159

Phase 2;Phase 3

China

NCT01267422
(ClinicalTrials.gov)

April 2011

27/12/2010

Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)

Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy

Leber Hereditary Optic Neuropathy

Drug: rAAV2-ND4

Bin Li

Huazhong University of Science and Technology

Completed

8 Years

60 Years

All

N/A

China